CD274 and neoplasm: We adopted CPS ≥ 20 as cutoff based on a previous clinical trial (Samstein et al. 2019), observing an association between tumor cell PD-L1 expression levels and the ORR for ICIs, consistent with previous studies conducted in CUP patients (Raghav, et al. 2022; Tanizaki et al. 2022).